This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
WORCESTER, Mass. and
TORONTO, Sept. 13, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT) (
www.generex.com), announced today presentation of early results from an efficacy study of an immunotherapeutic in triple negative breast cancer patients. The immunotherapeutic is being developed by Antigen Express, Inc. (
www.antigenexpress.com), a wholly owned subsidiary of Generex. The results will be presented on
Friday, September 14, 2012 at the 2012 Breast Cancer Symposium organized by the American Society of Clinical Oncology (ASCO) being held in
San FranciscoSeptember 13 - 15.
The presentation, entitled
Early Efficacy Analysis of the AE37 Vaccine in Patients with HER2 Low-Expressing and Triple Negative Breast Cancer, will be made by Dr.
Elizabeth Mittendorf, who is the Principal Investigator of the ongoing Phase II trial of the immunotherapeutic AE37. While the study showed an overall reduction of 42% in the risk of relapse in all patients of the study who received the vaccine, the reduction in the risk of relapse was 66% in patients with low expression of the HER2 oncoprotein who were classified as having triple negative breast cancer.
The immunotherapeutic being developed by Antigen Express is designed to generate an immune response specifically targeting tumor cells expressing the HER2 oncoprotein. While this is the same target as that of the widely used drug Herceptin, the immune response elicited by AE37 is capable destroying cells expressing lower levels of HER2 that are required for sensitivity to Herceptin. "The suggestion of the ability of AE37 to prevent recurrence in breast cancer patients is very encouraging," said Dr. Mittendorf. "This is particularly so in patients with triple negative disease, for whom treatment options are extremely limited," she added.
Antigen Express is currently in late stage Phase II clinical development of AE37. Based upon positive data obtained to date, the company is proceeding with plans for a pivotal Phase III trial.